Clinical Trial Update: Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of SCM-AGH in moderate to severe atopic dermatitis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• SCM-AGH

Snippet

Sponsor: SCM Lifescience Co., LTD. | Conditions: Dermatitis, Atopic | Phase 1, Phase 2 | Status: COMPLETED